Muddassir Sana, MD
Pain Medicine · Gonzales, LANPI 1609023944
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Boston Scientific at 36.3% of the total. Reporting peaked in 2021 at $1,563 and has fallen 54.3% since, to $714 in 2025.
Across 29 payments — averaging $139.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Nevro Corp.$1K
- Pacira Pharmaceuticals Incorporated$679
- Abbott$314
- AbbVie$107
- Stryker$38
- plus $215 from 10 others
What the payments were for
- Speaking & faculty fees$1,18629%
- Travel & lodging$1,41335%
- Food & beverage$1,45936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $1,474 |
| Nevro Corp. | 2 | $1,231 |
| Pacira Pharmaceuticals Incorporated | 3 | $679 |
| Abbott | 3 | $314 |
| AbbVie | 1 | $107 |
| Stryker | 1 | $38 |
| Nalu Medical, Inc. | 2 | $34 |
| Edwards Lifesciences | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Bioventus LLC | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$1,186
- WAVEWRITER ALPHA$749
- Iovera$616
- GENERAL PAIN MANAGEMENT$533
- ETERNA$152
- Superion Indirect Decompression System$145
- Proclaim IPG$144
- BOTOX$107
How this compares
$4,058 in reported general payments places this provider in the 55th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 114 | $9,461 |
| Gabapentin | 168 | $1,934 |
| Methocarbamol | 99 | $1,645 |
| Pregabalin | 107 | $1,599 |
| Diclofenac Sodium | 23 | $558 |
| Cyclobenzaprine Hcl | 42 | $447 |
| Tizanidine Hcl | 46 | $334 |
| Celecoxib | 14 | $274 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $272 |
| Meloxicam | 55 | $123 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Gonzales
- Thomas MyersMandeville$118K
- Alan KayeNew Orleans$76K
- Derrick DeanTerrytown$68K
- Hazem EissaNew Orleans$50K
- Robert OwensNew Orleans$47K
- Gassan ChaibanLake Charles$30K
- Yashar EshraghiNew Orleans$22K
- Prathima AnandiShreveport$19K
- Jason GremillionBaton Rouge$19K
- Eric StockwellMetairie$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.